AMLX
Amylyx Pharmaceuticals, Inc.
$17.77
-0.61 (-3.32%)
At close · Jul 10
Market Cap
$1.98B
Shares
111,186,317
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.77
Open$18.34
Day$17.15–18.34
52W$7.13–19.15
Avg vol 30d1.6M
Short int14.4M · 12.9% float · 7.1d
Short vol69%
Last earningsMay 7, 2026
DataJan 2022–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
+16%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
89%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+33%
trailing
6-month return
+31%
trailing
YTD return
+47%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
5 of 172 funds reported for Jun 30 · net +720 sh shares
Insider flow
Accumulating
Net +$51.3K over 90 days · 0% sells
Short interest
Rising
12.94% of float · ▲ +9.6% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
172 holders — mid 3-yr range
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
+1613%
Y/Y
EPS growth
+65%
Y/Y
Free cash flow
$-123.5M
Balance sheet
$226.7M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
89%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $14 — 50d above 200d
Institutional flow
Accumulating
5 of 172 funds reported for Jun 30 · net +720 sh shares
Insider flow
Accumulating
Net +$51.3K over 90 days · 0% sells
Short interest
Rising
12.94% of float · ▲ +9.6% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
172 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $7
Now $18 · 89%
52-wk high $19
vs 200-day avg +23%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| estimated PBH population in the U.S. (post sleeve gastrectomy and Roux-en-Y gastric bypass) | 160,000 | Q1 2026 call | — |
| expanded access program participants | 250 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMLX
this stock
Amylyx Pharmaceuticals, Inc.
|
$1.98B | +47.1% | +1612.9% | — | 12.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$52.88B | +6.2% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$50.15B | +3.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.98B | -3.5% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMLX | -2.7% | +32.8% | +31.4% | -1.1% | +47.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -4.1% | +28.7% | +22.4% | -2.2% | +36.4% |